Videos and Webinars

For the treatment of CAP, in which patient types do you think ceftaroline is the most valuable and where do you fit ceftaroline into the current treatment pathway?

In this video, Prof. Matteo Bassetti describes the treatment of CAP, including in which patient types Ceftaroline fosamil is most valuable and where Ceftaroline fosamil fits into the current treatment pathway.


GCMA number: PP-ZFO-IND-0287

Go to top

How does non-response to initial treatment affect outcomes in community-acquired pneumonia?

This video describes how non-response to initial treatment affects the outcomes in CAP.


GCMA number: PP-ZFO-IND-0291

Go to top

How do ceftaroline characteristics compare with other agents currently being used in CAP?

This video describes how Ceftaroline fosamil characteristics compare with other agents currently being used in CAP.


GCMA number: PP-ZFO-IND-0290

Go to top

What is the efficacy of ceftaroline in high-risk patients, such as those with comorbidities, in Phase III CAP trials (FOCUS 1 & 2 and Asia CAP)

In this video, Prof. Tobias Welte answers the question, 'What is the efficacy of Ceftaroline fosamil in high-risk patients, such as those with comorbidities, in Phase III CAP trials (FOCUS 1 & 2, and Asia CAP)?'


GCMA number: PP-ZFO-IND-0298

Go to top

Zinforo® in patient with post-influenza bacterial pneumonia

This video provides information about Ceftaroline fosamil on - Patient Case Animation- Case 1 (CAP).


GCMA number: PP-ZFO-IND-0307

Go to top

How does the proportion of adverse events in ceftaroline clinical trials compare to real-world experience?

This video describes information on how the proportion of adverse events in Ceftaroline fosamil clinical trials compare to the real-world experience?

Prof. Matthew Dryden and Prof. Tobias Welte describes clinical trials versus the real-world experience.


GCMA number: PP-ZFO-IND-0309

Go to top

Zinforo® binds to all six PBPs that have been identified in S. pneumoniae (PBP1A, 1B, 2x, 2A/B and 3)

This video describes the mechanism of action of Zinforo® (Ceftaroline fosamil) on indication CAP and cSSTI .


GCMA number: PP-ZFO-IND-0302

Go to top

Zinforo® in patients with multiple comorbidities

This video provides information about Ceftaroline fosamil  on - Patient Case Animation- Case 3 (CAP).


GCMA number: PP-ZFO-IND-0314

Go to top

Zinforo® is recommended by official practice guidelines (IDSA and ATS)

This video focusses on the IDSA publication of Zinforo.


GCMA number: PP-ZFO-IND-0315

Go to top

Zinforo® provides swift, decisive action against CAP with a rapid response at Day 4

This video describes the clinical efficacy of Zinforo® in CAP.


GCMA number: PP-ZFO-IND-0317

Go to top

Zinforo® provides rapid and potent activity against key causative pathogens in CAP and cSSTI

This video describes information on how Zinforo® provides rapid and potent activity against the key causative pathogens in CAP.


GCMA number: PP-ZFO-IND-0326

Go to top

Zinforo® provides clinical stability for the treatment of CABP

This video highlights the use of ceftaroline fosamil, which provides clinical stability over ceftriaxone at Day 4 for the treatment of CABP.


GCMA number: PP-ZFO-IND-0386

Go to top

 

ATS, American Thoracic Society; CABP, community-acquired bacterial pneumonia; CAP, community-acquired pneumonia; cSSTI, complicated skin and soft tissue infection; FOCUS, ceFtarOline Community-acquired pneUmonia trial versuS ceftriaxone in hospitalised patients; IDSA, Infectious Diseases Society of America; MOA, mode of action; PBPs, penicillin binding proteins.

PP-ZFO-IND-0416 13 June 2022
Please click on Prescribing Information link to view safety and adverse events information of Zinforo.
For the use only of registered medical practitioners, or a hospital or a laboratory.

In which cSSTI patient types do you think ceftaroline is most valuable and what are the risk factors for poor prognosis?

In this video, Prof. Matthew Dryden describes the treatment of cSSTI, including in which patient types Ceftaroline fosamil is most valuable and what are the risk factors associated with its poor prognosis.


GCMA number: PP-ZFO-IND-0289

Go to top

What is the efficacy of ceftaroline in high-risk patients, such as those with comorbidities, in Phase III cSSTI trials (CANVAS 1 & 2 and COVERS)?

This video describes the efficacy of Ceftaroline fosamil in high-risk patients, such as those with comorbidities, in the Phase III cSSTI trials (CANVAS 1, CANVAS 2 and COVERS).


GCMA number: PP-ZFO-IND-0292

Go to top

How does the proportion of adverse events in ceftaroline clinical trials compare to real-world experience?

This video describes information on how the proportion of adverse events in Ceftaroline fosamil clinical trials compare with that in the real-world experience.

Prof. Matthew Dryden and Prof. Tobias Welte describes clinical trials versus the real-world experience.


GCMA number: PP-ZFO-IND-0309

Go to top

How do ceftaroline requirements regarding routine monitoring and dose adjustment depending on body weight etc. compare with other agents, such as vancomycin?

In this video, Prof. Christian Eckmann answers the question, ‘How do Ceftaroline fosamil requirements regarding routine monitoring and dose adjustment depend on factors, such as body weight, compared with other agents, such as vancomycin?’


GCMA number: PP-ZFO-IND-0310

Go to top

Considering appropriate therapy in patients with cSSTI

This video provides information about considering the appropriate therapy in patients with cSSTI, which was presented in the Zinforo Satellite Symposium at the ECCMID 2018 and filmed post event for educational purposes by Prof. Christian Eckmann.


GCMA number: PP-ZFO-IND-0300

Go to top

Zinforo® binds with high affinity to PBP 1, 2 and 3 in MSSA and PBP 2a in MRSA.

This video describes the MOA of Zinforo® (ceftaroline fosamil) on the indications, CAP and cSSTI.

 


GCMA number: PP-ZFO-IND-0302

Go to top

Zinforo® in patient with cellulitis in cheek

This video presenting Patient Case Animation - Case 2 (cSSTI) about Ceftaroline fosamil in patients with cellulitis in the cheek.


GCMA number: PP-ZFO-IND-0328

Go to top

Zinforo® in patient with cSSTI not responding to initial treatment

This video presenting Patient Case Animation - Case 4 (cSSTI) about Ceftaroline fosamil in patients with cSSTI not responding to the initial treatment.


GCMA number: PP-ZFO-IND-0303

Go to top

Zinforo® provides rapid and potent activity against key causative pathogens in CAP and cSSTI

This video describes information on how Zinforo® provides rapid and potent activity against the key causative pathogens in cSSTI.


GCMA number: PP-ZFO-IND-0326

Go to top

For the treatment of cSSTI, in which patient types do you think ceftaroline is most valuable and where you fit ceftaroline into the current treatment pathway?

In this video, Prof. Matteo Bassetti describes the treatment of cSSTI, including in which patient types Ceftaroline fosamil is most valuable and where Ceftaroline fosamil fits into the current treatment pathway.


GCMA number: PP-ZFO-IND-0319

Go to top

Ceftaroline fosamil versus vancomycin plus aztreonam for the treatment of cSSTI

This video provides information on the CANVAS 1 and CANVAS 2 trials, which analyse the clinical response at Day 3 in 2 Phase III trials of ceftaroline fosamil versus vancomycin plus aztreonam in the treatment of cSSTIs.


GCMA number: PP-ZFO-IND-0387

Go to top

 

CANVAS, CeftAroliNe Versus vAncomycin in Skin and skin structure infections; CAP, community-acquired pneumonia; COVERS, CeftarOline versus Vancomycin and aztrEonam tReating cSSTI; cSSTI, complicated skin and soft tissue infection; ECCMID, European Congress of Clinical Microbiology and Infectious Diseases; MOA, mode of action; MRSA, Methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; PBP, penicillin binding protein.

PP-ZFO-IND-0416 13 June 2022
Please click on Prescribing Information link to view safety and adverse events information of Zinforo.
For the use only of registered medical practitioners, or a hospital or a laboratory.